AI Article Synopsis

  • The study investigates the effectiveness of cell-free Mycobacterium tuberculosis DNA (cf-TB) testing as a biomarker for diagnosing tuberculous pleurisy (TP) due to challenges with low bacterial levels in pleural effusion samples.
  • Conducted across 11 research sites in China, the study analyzed PE samples from 1344 patients suspected of TP, using techniques like Xpert MTB/RIF and mycobacterial culture alongside cf-TB testing.
  • Results revealed that cf-TB testing had a significantly higher sensitivity (73.6%) for definite TP compared to Xpert (40.8%) and mycobacterial culture (54.2%), while maintaining 100% specificity across all tests.

Article Abstract

Background: The diagnosis of tuberculous pleurisy (TP) presents a significant challenge due to the low bacterial load in pleural effusion (PE) samples. Cell-free Mycobacterium tuberculosis DNA (cf-TB) in PE samples is considered an optimal biomarker for diagnosing TP. This study aimed to evaluate the applicability of cf-TB testing across diverse research sites with a relatively large sample size.

Methods: Patients suspected of TP and presenting with clinical symptoms and radiological evidence of PE were consecutively enrolled by treating physicians from 11 research sites across 6 provinces in China between April 2020 and August 2022. Following centrifugation, sediments obtained from PE were used for Xpert MTB/RIF (Xpert) and mycobacterial culture, while the supernatants were subjected to cf-TB testing. This study employed a composite reference standard to definite TP, which was characterized by any positive result for Mycobacterium tuberculosis (MTB) through either PE culture, PE Xpert, or pleural biopsy.

Results: A total of 1412 participants underwent screening, and 1344 (95.2%) were subsequently enrolled in this study. Data from 1241 (92.3%) participants were included, comprising 284 with definite TP, 677 with clinically diagnosed TP, and 280 without TP. The sensitivity of cf-TB testing in definite TP was 73.6% (95% CI 68.2-78.4), significantly higher than both Xpert (40.8%, 95% CI 35.3-46.7, P < 0.001) and mycobacterial culture (54.2%, 95% CI 48.4-59.9, P < 0.001). When clinically diagnosed TP was incorporated into the composite reference standard for sensitivity analysis, cf-TB testing showed a sensitivity of 46.8% (450/961, 95% CI 43.7-50.0), significantly higher than both Xpert (116/961, 12.1%, 95% CI 10.2-14.3, P < 0.001) and mycobacterial culture (154/961, 16.0%, 95% CI 13.8-18.5, P < 0.001). The specificities of cf-TB testing, Xpert, and mycobacterial culture were all 100.0%.

Conclusions: The performance of cf-TB testing is significantly superior to that of Xpert and mycobacterial culture methods, indicating that it can be considered as the primary diagnostic approach for improving TP detection. Trial registration The trial was registered on Chictr.org.cn (ChiCTR2000031680, https://www.chictr.org.cn/showproj.html?proj=49316 ).

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11340177PMC
http://dx.doi.org/10.1186/s40779-024-00567-yDOI Listing

Publication Analysis

Top Keywords

mycobacterium tuberculosis
12
cf-tb testing
12
cell-free mycobacterium
8
tuberculosis dna
8
pleural effusion
8
tuberculous pleurisy
8
accuracy cell-free
4
testing
4
dna testing
4
testing pleural
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!